AndroBioSys is pursuing a dual strategy for treating prostate disease: it's running a contract research business while it builds a therapeutic pipeline. One of the company's programs is based on the discovery of a novel enzyme that converts testosterone to dihydrotestosterone, which is the most potent activator of the androgen receptor. Another program focuses on a target on prostate cancer stem cells that makes them resistant to chemotherapy. The company is working on developing an assay to detect circulating prostate cancer stem cells, which could guide physicians in determining how aggressively to treat the patient. The next step would be to develop a therapy capable of eliminating such cells.
73 High Street
Buffalo, NY 14203
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
Supernus agreed to pay $561m upfront plus a contingent value right that could add $234m to buy Sage, topping a previously rejected offer from Biogen.
The drugmaker presented data at a lymphoma meeting showing strong efficacy for the CAR-T in marginal zone lymphoma, the second most common indolent lymphoma.
First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.
